Ruxoprubart for hemoglobinuria, paroxysmal

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Feb 2023: Trial registered, NCT05731050

The trials

NCT05731050: Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

State
Not started
Phase
Phase 2
People
6 planned
Started
Jun 2026
Primary completion
Sep 2027
Arms
NM8074
Results
None posted
  1. 16 Feb 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.